• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

multiple myeloma

Horseshoe magnet attracting metallic pawn people
Biotech

Biotech shares first data for in vivo CAR-T that attracted AZ

Two patients had all signs of their multiple myeloma disappear completely after treatment, while two others saw partial responses to the cell therapy.
Darren Incorvaia Jul 7, 2025 2:27pm
multiple myeloma cells blood flow cancer blood cancer

Pfizer-backed CellCentric secures $120M for ph. 3 myeloma trial

May 19, 2025 9:25am
chop down cut tree chainsaw ax

C4T halts BRAF degrader work to save cash for cemsidomide

May 7, 2025 7:00am
Boston Harbor skyline

British biotech CellCentric expands to Boston, plans hiring push

Apr 2, 2025 1:53pm
concept of growth and then decline

Genmab axes anti-CD38 antibody after losing J&J support

Mar 10, 2025 2:13pm
Three blocks displaying from left to right a person a handshake and another person

Exicure buys GPCR's US unit and clinical-stage blood cancer drug

Jan 23, 2025 5:01am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings